LDFR
VKTX icon

Lehman & Derafelo Financial Resources’s Viking Therapeutics VKTX Stock Holding History

Lehman & Derafelo Financial Resources’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,000
Closed -$58K – 273
2020
Q3 		$58K Hold
10,000
– – 0.02% 168
2020
Q2 		$72K Buy
+10,000
New +$66.4K 0.03% 150

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Lehman & Derafelo Financial Resources's VKTX Position: Q4 2020 in Review

Lehman & Derafelo Financial Resources sold out of Viking Therapeutics (VKTX) in Q4 2020, closing a stake of 3,050 shares — an estimated $18K sold.

Lehman & Derafelo Financial Resources first reported a position in VKTX in Q2 2020 and held it in 2 quarters. The position peaked at $22K in Q2 2020. 143 funds tracked by Wall St. Rank hold VKTX as of Q4 2020.

  • Lehman & Derafelo Financial Resources reported no remaining Viking Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Lehman & Derafelo Financial Resources sold 3,050 Viking Therapeutics shares in Q4 2020, an estimated $18K.
  • Lehman & Derafelo Financial Resources first reported a position in Viking Therapeutics in Q2 2020 and held it in 2 quarters.
  • Lehman & Derafelo Financial Resources's Viking Therapeutics position peaked at $22K in Q2 2020.
  • 143 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2020.

Based on Lehman & Derafelo Financial Resources's 13F filing for Q4 2020, filed 20 Jan 2021.